CASI PHARMACEUTICALS INC's ticker is CASI and the CUSIP is 14757U109. A total of 3 filers reported holding CASI PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $315,000 | -62.9% | 389,273 | -63.3% | 0.00% | – |
| Q4 2021 | $850,000 | +208.0% | 1,062,128 | +357.6% | 0.00% | – |
| Q3 2021 | $276,000 | +318.2% | 232,109 | +747.2% | 0.00% | – |
| Q1 2021 | $66,000 | -15.4% | 27,396 | +3.1% | 0.00% | – |
| Q4 2020 | $78,000 | +90.2% | 26,580 | -0.3% | 0.00% | – |
| Q3 2020 | $41,000 | +41.4% | 26,670 | +87.6% | 0.00% | – |
| Q1 2020 | $29,000 | -61.3% | 14,219 | -36.5% | 0.00% | – |
| Q3 2019 | $75,000 | -65.6% | 22,402 | -67.0% | 0.00% | – |
| Q2 2019 | $218,000 | +159.5% | 67,865 | +565.9% | 0.00% | – |
| Q2 2018 | $84,000 | -85.7% | 10,191 | -92.8% | 0.00% | – |
| Q1 2018 | $587,000 | +633.8% | 140,680 | +473.2% | 0.00% | – |
| Q4 2017 | $80,000 | +321.1% | 24,541 | +37.5% | 0.00% | – |
| Q2 2017 | $19,000 | +46.2% | 17,850 | +32.1% | 0.00% | – |
| Q4 2015 | $13,000 | – | 13,511 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| IDG-Accel China Growth Fund III Associates L.P. | 7,973,536 | $23,522,000 | 27.18% |
| Consonance Capital Management LP | 7,576,431 | $22,350,000 | 2.09% |
| Wellington Shields & Co., LLC | 1,812,769 | $5,348,000 | 1.92% |
| Wellington Shields Capital Management, LLC | 2,071,765 | $6,112,000 | 0.82% |
| Ikarian Capital, LLC | 1,268,154 | $3,741,000 | 0.16% |
| Sio Capital Management, LLC | 203,432 | $600,000 | 0.12% |
| Zebra Capital Management LLC | 11,182 | $33,000 | 0.04% |
| FEDERATED HERMES, INC. | 7,000,000 | $20,650,000 | 0.04% |
| GSA CAPITAL PARTNERS LLP | 52,146 | $154,000 | 0.02% |
| BOOTHBAY FUND MANAGEMENT, LLC | 161,949 | $478,000 | 0.02% |